A Meningococcus B Super Spreader Event in Kent, and a Reappraisal of Routine MenB Vaccination for Younger People

An outbreak of group B meningococcus infection among young people is said to have originated at the Club Chemistry nightclub in Canterbury, Kent, where several of the victims were among 2,000 partygoers on the nights of 5, 6, and 7 March 2026. The ‘ground zero’ nightclub, which provides “different eclectic sounds ranging from chart to dance, RnB and hip hop on 3 floors”, has been closed until further notice. A crowded nightclub provides an environment conducive to the spread of contagious illness through close social contact, including dancing close together, kissing, coughing and sneezing, and vape sharing. Those affected were reported to have first developed symptoms by 10 March. East Kent Hospitals NHS Trust notified the first case of suspected meningitis to the UK Health Security Agency (UKHSA) on 13 March. A second case, linked to the University of Kent, was reported from France the following day. Fifteen cases of invasive meningococcal disease had been confirmed as of 18 March. Two of the victims have unfortunately lost their lives. The rapid spread of the outbreak has led Professor Susan Hopkins, CEO of the UKHSA, to describe it a “super spreader event.” Cases have since been reported among students at four schools in Kent.

 As many as 5,000 students staying at the University of Kent’s Canterbury Campus Halls of Residence will be targeted and offered two doses of MenB vaccine for longer- term protection. In the short term, preventative treatment with ciprofloxacin, a broad-spectrum antibiotic, has been offered, from 15 March onwards, to those who attended Club Chemistry on 5, 6 and 7 March, and to close contacts of the victims, among others.  

MenC vaccination, against meningococcus group C bacteria, was introduced to the UK in 1999. Since then, the MenACWY vaccine, which covers A, C, W, and Y groups of the same organism has become available, is routinely offered to teenagers in school years 9 and 10, and can be obtained on the NHS up to the age of 25 years. MenB vaccination, against group B meningococci, was added to the routine childhood immunisation schedule in 2015, covering babies and infants thereafter, but leaving out young people born before the year of introduction. The vaccine can, however, be obtained privately.

Meningococci, the plural form of meningococcus, are described as “Gram-negative diplococci.”  These organisms may be found in some people in the back of the nose and throat, but normally do not cause harm to the unaware carriers. When seen under the microscope, the organisms of Neisseria meningitidis (the scientific name for the meningococcus) are spherical-shaped, occur in pairs, and take on a pink to red colour when subjected to a Gram stain.  Multiple serogroups, which share common antigens and can be identified by serological assays, have been identified.

Invasive meningococcal infections are life-threatening emergencies, where treatment has to be initiated on mere suspicion, before the diagnosis can be confirmed by laboratory tests on blood or cerebrospinal fluid specimens. Wherever possible, the first-responding healthcare professional should inject a single dose of ceftriaxone, a cephalosporin antibiotic, provided this does not come in the way of rapid transfer to a hospital. To put it somewhat crudely, “better a living problem than a dead certainty.” All suspected cases have to be reported to the responsible UKHSA health protection team to ensure adequate monitoring of the situation on the ground.

The early diagnosis of invasive meningococcal infections, which comprise meningitis and septicaemia, is key to successful treatment. Meningitis refers to inflammation of the protective membranes that cover the brain and spinal cord, while septicaemia is a more refined term for blood poisoning.  Unfortunately, it can be difficult to recognise either condition early enough, as the initial symptoms can be ‘non-specific’ and overlap with those of other commoner and, often less serious, bacterial and viral infections.

Meningitis typically produces varying combinations of high fever, severe headache, intolerance of bright lights, drowsiness, confusion, and neck stiffness. The meningococcal skin rash, characteristic of septicaemia, starts as small, red or brown pin-point-sized spots which spread rapidly and coalesce into red or purple bruises, or blood blisters, which can be found anywhere in the body. The rash does not fade under firm pressure from a clear glass, as it is due to leakage of blood through inflamed and damaged walls of blood vessels. The rash can be difficult to recognise on black, brown, or tanned skin. Furthermore, not everyone with invasive meningococcal disease will develop a skin rash. Septicaemia can also be associated with severe leg pain, and cold hands and feet.

Rapid deterioration with invasive meningococcal infection occurs from circulatory failure and the effects of increased pressure on the brain within the skull. This can lead to untimely death, while survivors often suffer life-changing sequelae such as permanent brain damage, hearing loss, and limb amputations.

The meningococcal super spreader event is yet another reminder of our vulnerability to disease-producing microbes, and once again draws attention to the imperative to be immunised against lethal infections for which vaccines are available. As always, it is important to look out for, and adhere to, all relevant advice from public health officials-the undoubted experts in this field. It remains for the authorities to decide whether MenB vaccination is ultimately offered to all teenagers and young adults who missed out, but remain vulnerable to meningococcus B infection.

Ashis Banerjee